Ticker LaunchIPO · ADTX
Aditxt, Inc.
Formerly ADiTx Therapeutics, Inc.; Aditx Therapeutics, Inc.
Aditxt, Inc. (ADTX) priced its initial public offering on Jul 1, 2020 at $9.00 per share, raising $11M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $46.6M. Dawson James was lead-left underwriter, joined by ViewTrade. Sheppard Mullin advised the company and Schiff Hardin advised the underwriters.
Aditxt, Inc. is a life sciences company based in Loma Linda, California, working on technologies to improve immune system health. Its pre-clinical immune reprogramming approach targets organ transplant rejection, autoimmune diseases and allergies, while its immune monitoring tool profiles a person's immune response.
- Status
- IPO
- Ticker
- ADTX
- Exchange
- Nasdaq Capital Market
- Priced
- Jul 1, 2020
- IPO price
- $9.00
- Raised
- $11M
- Market cap at IPO price
- $46.6M
- First filed
- Jan 15, 2020
- Underwriters
- Dawson James and ViewTrade
- Company counsel
- Sheppard Mullin
- Underwriters' counsel
- Schiff Hardin
- Sector
- Biotech & pharma
- Country / state
- VA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 15, 2020
- Latest amendment Jun 25, 2020
- Final prospectus (424B4) Jul 1, 2020
- All filings on EDGAR CIK 1726711
Other Biotech & pharma IPOs in 2020
- Poseida Therapeutics, Inc.PSTX · Jul 10, 2020 · $224M
- Amryt Pharma plcAMYT · Jul 8, 2020
- Akouos, Inc.AKUS · Jun 26, 2020 · $212.5M
- Fusion Pharmaceuticals Inc.FUSN · Jun 26, 2020 · $212.5M
- Forma Therapeutics Holdings, Inc.FMTX · Jun 22, 2020 · $277.6M
- Biora Therapeutics, Inc.Jun 22, 2020 · $100M